<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Acquired interstitial or complete losses of chromosome 5 are recurring anomalies associated with preleukemic <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> with a poor prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies have delineated a potential <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid tumor</z:e> suppressor locus to a &lt;2.4-Mb interval between the genes for IL9 and EGR1 on 5q31 </plain></SENT>
<SENT sid="2" pm="."><plain>In this report, we have localized the SMAD5 gene, a homologue of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes SMAD4/<z:chebi fb="5" ids="53074">DPC</z:chebi>-4 and SMAD2/JV18.1, to the minimal <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid tumor</z:e> suppressor locus and characterized its open reading frame and genomic organization </plain></SENT>
<SENT sid="3" pm="."><plain>SMAD5 transcripts are readily detectable in hematolymphoid tissues and leukemic blasts </plain></SENT>
<SENT sid="4" pm="."><plain>Absence of intragenic mutations in the remaining SMAD5 allele of leukemic patients and multiple <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> cell lines prescreened for loss of heterozygosity suggests that SMAD5 may not be a common target of somatic inactivation in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
</text></document>